OASIS® Matrix Products

A value-based, natural extracellular matrix to help meet the challenge of hard-to-heal wounds1

OASIS BURN MATRIX 3x3.5 fen.png

A simple solution for complex wounds

OASIS Matrix Products are naturally derived scaffolds of extracellular matrix (ECM), composed of porcine small intestinal submucosa (SIS)1 and indicated to manage a wide range of acute and chronic wounds.

  • Similar composition to the human dermis2-13 providing pathways to cellular migration and vascular growth14
  • Universal and cost effective - intended for versatility and affordability in routine clinical use
  • 24-month shelf life at room temperature, terminally sterilized and not subject to tissue tracking requirements of the Joint Commission*
  • Shown to achieve greater effectiveness in managing chronic leg ulcers15 and diabetic foot ulcers,16 achieving improved epithelialization and wound closure compared to standard care alone15,16
36-OASIS-US-ONLY-840x840.png

Disclaimer

*The Joint Commission is an independent, not-for-profit organization. Details available on request.

INTENDED USE: OASIS® Matrix and OASIS MICRO are indicated for the management of wounds including: partial- and full-thickness wounds, pressure ulcers, venous ulcers, chronic vascular ulcers, tunneled and/or undermined wounds, diabetic ulcers, trauma wounds (abrasions, lacerations, second-degree burns, skin tears), draining wounds, surgical wounds (donor sites/grafts, post-Mohs surgery, post-laser surgery, podiatric, wound dehiscence).

CONTRAINDICATIONS: This device is derived from a porcine source and should not be used in patients with known sensitivity to porcine material.

This device is not indicated for use in third-degree burns.

PRECAUTION: OASIS® Matrix and OASIS MICRO should not be applied until excessive exudate, bleeding, acute swelling, and infection are controlled.

POTENTIAL COMPLICATIONS: The following complications are possible. If any of these conditions occur, the device should be removed: infection, chronic inflammation (initial application of wound dressings may be associated with transient, mild, localized inflammation), allergic reaction, excessive redness, pain, swelling, or blistering.

OASIS Matrix Products are manufactured by: Cook Biotech, Inc. 1425 Innovation Place, West Lafayette, IN 47906.

OASIS Matrix Products are distributed by: Advanced Wound Management Smith+Nephew, Inc. Fort Worth, TX 76109

Recall and Complaints

Customer will provide such support and assistance as S+N may reasonably request in the event of a general or limited voluntary or mandatory recall of the Product(s). Customer shall promptly report any complaint in respect of the Products to complaints@smith-nephew.com.

Terms & Conditions and Warranties

Citations
  1. Nherera LM, et al. Ostomy Wound Manage. 2017;63(12):38-47.
  2. Badylak SF. Semin Cell Dev Biol. 2002;13(5):377-383.
  3. Frantz C, et al. J Cell Sci. 2010;123(Pt 24):4195-4200.
  4. Hodde J, et al.. J Mater Sci Mater Med. 2007;18(4):537-543.
  5. Internal Cook Biotech Document: 97-010 VIIA.
  6. Internal Cook Biotech Document: 97-010 VIIB.
  7. Internal Cook Biotech Document: 07-057.
  8. Internal Cook Biotech Document: 00-027.
  9. Brown B, et al. Tissue Eng. 2006;12(3):519-526.
  10. Internal Cook Biotech Document: 98-084.
  11. Hodde JP, et al. Tissue Eng. 1996;2(3):209-217.
  12. Internal Cook Biotech Document: 96-006.
  13. Hurst RE, et al. J Biomater Sci Polym Ed. 2001;12(11):1267-1279.
  14. Nihsen ES, et al. Adv Skin Wound Care. 2008;21(10):479-486.
  15. Mostow EN, et al. J Vasc Surg. 2005;41(5):837-843.
  16. Cazzell SM, et al. Adv Wound Care. 2015;4(12):711-718.
  17. Barendse-Hofmann MG, et al. Wounds. 2007;19(10):258-263.
  18. Aboulssa A, et al. Wounds. 2015;27(11):313-318.
  19. Hodde JP, et al. Am J Clin Dermatol. 2007;8(2):61-66.
  20. Chen WY, et al. Wound Repair Regen. 1999;7(2):79-89.
  21. Sarrazin S, et al. Cold Spring Harb Perspect Biol. 2011;3(7):a004952.
  22. McPherson JM, et al. The Molecular and Biology of Wound Repair. New York: Plenum Press, 1988:471-491.
  23. Raman R, et al. Chem Biol. 2005;12:267-277.
  24. Sottile J, et al. Mol Biol Cell. 2002;13(10):3546-3559.
  25. Tzu J, et al. Int J Biochem Cell Biol. 2008;40:199-214.
  26. Gubbiotti MA, et al. Matrix Biol. 2016;55:7-21.
  27. Cook Biotech, Inc. internal document #04-062.
  28. Nihsen ES, et al. J Wound Ostomy Continence Nurs. 2007;34(3S):S65.
  29. Cook Biotech, Inc. internal document #07-001
  30. OASIS Wound Matrix, OASIS Burn Matrix, OASIS Ultra Tri-Layer Matrix, and OASIS MICRO Instructions for Use. Cook Biotech Inc.

Title

Text

Explore